Nonseminomatous germ cell cancer of the testis. Reducing treatment-related morbidity in patients with disseminated disease.

Abstract

Fourteen previously untreated patients with metastatic nonseminomatous germ cell cancer of the testis (NSGC) were treated with a modified VAB-4 regimen which was designed to reduce treatment-related morbidity. Nine of 10 patients with minimal disease and the only patient with advanced pulmonary disease achieved a complete response (CR) with chemotherapy alone. Two of three partial responders with advanced abdominal disease were converted to CR status with radiotherapy and/or surgery. None of the 12 CRs have relapsed (median duration of follow-up, 28+ months). We observed no granulocytopenic fever or permanent renal insufficiency. These results indicate that NSGC patients with a low tumor burden can be spared substantial toxicity without adversely affecting complete response rates.

• Authors: B R Paschal, H B Muss, F Richards 2nd, M R Cooper, D R White, D V Jackson, J J Stuart, C L Spurr
• Journal: Cancer (Cancer) Vol. 50 Issue 9 Pg. 1742-5 (Nov 01 1982) ISSN: 0008-543X [Print] United States
• PMID: 6288223 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (adverse effects)
• Drug Administration Schedule
• Drug Therapy, Combination
• Humans
• Leukopenia (chemically induced)
• Male
• Neoplasm Metastasis
• Neoplasm Staging
• Neoplasms, Germ Cell and Embryonal (drug therapy, pathology)
• Prognosis
• Testicular Neoplasms (drug therapy, pathology)